Cantor Fitzgerald Comments on VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($2.20) for the year. Cantor Fitzgerald has a "Overweight" rating and a $5.73 price target on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share.

Several other brokerages also recently commented on VYGR. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com cut shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 target price for the company. Citigroup began coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a "buy" rating and a $12.00 price target on the stock. Finally, Wedbush assumed coverage on Voyager Therapeutics in a report on Friday, November 29th. They issued an "outperform" rating and a $11.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $15.97.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock traded up $0.11 during trading hours on Wednesday, reaching $5.33. The company had a trading volume of 120,929 shares, compared to its average volume of 360,544. Voyager Therapeutics has a 12-month low of $4.99 and a 12-month high of $10.66. The company has a 50-day moving average price of $5.84 and a 200 day moving average price of $6.67. The firm has a market cap of $291.18 million, a price-to-earnings ratio of 7.51 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the previous year, the business earned ($0.59) earnings per share.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 10,778 shares of company stock worth $58,548 over the last ninety days. 4.53% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock worth $41,132,000 after purchasing an additional 528,000 shares during the last quarter. Great Point Partners LLC purchased a new position in Voyager Therapeutics in the second quarter worth about $12,668,000. Geode Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock worth $6,316,000 after buying an additional 6,740 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Voyager Therapeutics in the third quarter worth approximately $6,192,000. Finally, American Century Companies Inc. grew its holdings in shares of Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock valued at $8,063,000 after buying an additional 249,659 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.